Enter the last name, specialty or keyword for your search below.
Dr. Jonathan Schneck is a professor of pathology, medicine and oncology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. His research focuses on T cell immunology.
His team pioneered the development of artificial white blood cells, called artificial antigen-presenting cells (aAPCs), which show promise in training animals' immune systems to fight diseases such as cancer. Using nano-aAPCs, his team recently trained the immune systems of mice to fight melanoma.
His lab’s current projects include studying the biophysical, genetic and environmental control of T cell receptor organization.
Dr. Schneck received his undergraduate degree from Yeshiva University. He earned his M.D.-Ph.D. in immunology from the Albert Einstein College of Medicine. After completing his degree, he trained in pediatrics at the Children's Hospital National Medical Center in Washington, D.C. From there he worked on the medical staff of the National Institute of Allergy and Immunology at the NIH in Bethesda, and did his postdoctoral training at the Laboratory of Immunology. He joined the Johns Hopkins faculty in 1990 as a junior faculty member.
Dr. Schneck was the PI of a research project funded by a $10.3 million NIH grant—the largest basic immunology grant ever received by Johns Hopkins. He has been recognized by the Johns Hopkins Lymphoma SPORE with a Career Development Award.
Dr. Schneck’s research focuses on the basic mechanisms that control immune responses. Specifically, he studies how cytotoxic T-cells, known as killer T cells—cells that help eliminate infections or cancers—get activated, recognize their targets and get turned off again. His team focuses on how to manipulate the immune system with the hopes of designing improved anti-cancer therapies by ramping up the immune system, or treating autoimmune disease and transplant patients with better immune system suppression.
The Schneck Lab studies the biophysical, genetic and environmental control of the T cell receptor. The research team has developed an acellular aAPC, a lego-like system that can be used to study T cells responses at a variety of different levels. Currently aAPC are being used to study manipulation of in vivo CTL responses and hold potential as a therapeutic approaches to augment both adoptive and active immunotherapy.
The team also develops approaches to understanding genetic regulation of glycosylation, among the most complex post-translational modifications with an extremely high level of diversity that has made it refractory to high-throughput analyses. One approach developed is a lectin microarray for defining mammalian cell surface glycan signatures and analyzing diverse cell processes including cell development and differentiation, cell-cell communication, pathogen-host recognition, and cell surface biomarker identification. On-going studies further explore use of this new technology in the identification of novel biomarkers.
de Melo AB, Nascimento EJ, Braga-Neto U, Dhalia R, Silva AM, Oelke M, Schneck JP, Sidney J, Sette A, Montenegro SM, Marques ET. T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-1 and -II binding motifs. PLoS Negl Trop Dis, 7(1):Jan. 31, 2013 (Epub ahead of print).
Webb TJ, Li X, Giuntoli RL 2nd, Lopez PH, Heuser C, Schnaar RL, Tsuji M, Kurts C, OelkeM, Schneck JP. Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res, 72(15):3744-52, 2012.
Lee JB, Oelke M, Ramachandra L, Canaday DH, Schneck JP. Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors. Immun Ageing, 8(6):4-11, 2011.
Phone: 410-614-4589
Immunology
Pathobiology
Cellular and Molecular Medicine
#TomorrowsDiscoveries: Giving Immune Response a Nano-Boost— Dr. Jonathan Schneck
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
